Janux Therapeutics, Inc.
NASDAQ:JANX
50.2 (USD) • At close September 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8.897 | 1.252 | 2.461 | 2.517 | 1.057 | 2.048 | 2.845 | 1.813 | 2.365 | 1.589 | 1.616 | 1.159 | 0.482 | 0.38 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.506 | 0.532 | 0.531 | 0.5 | 0.471 | 0.453 | 0.403 | 0.249 | 0.108 | 0.081 | 0.064 | 8.406 | 4.737 | 1.925 | 0.985 | 0.834 | 0.673 | 0.549 |
| Gross Profit
| 8.391 | 0.72 | 1.93 | 2.017 | 0.586 | 1.595 | 2.442 | 1.564 | 2.257 | 1.508 | 1.552 | -7.247 | -4.255 | -1.545 | -0.985 | -0.834 | -0.673 | -0.549 |
| Gross Profit Ratio
| 0.943 | 0.575 | 0.784 | 0.801 | 0.554 | 0.779 | 0.858 | 0.863 | 0.954 | 0.949 | 0.96 | -6.253 | -8.828 | -4.066 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 14.898 | 14.07 | 12.241 | 11.892 | 14.924 | 15.865 | 15.434 | 13.737 | 14.086 | 10.184 | 11.169 | 8.406 | 4.737 | 1.925 | 0.985 | 0.834 | 0.673 | 0.549 |
| General & Administrative Expenses
| 7.821 | 7.343 | 6.357 | 6.438 | 6.881 | 6.464 | 5.677 | 6.098 | 5.54 | 4.947 | 3.937 | 3.656 | 1.997 | 0.739 | 0.67 | 0.422 | 0.433 | 0.277 |
| Selling & Marketing Expenses
| -0.506 | -0.532 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 7.315 | 6.811 | 6.357 | 6.438 | 6.881 | 6.464 | 5.677 | 6.098 | 5.54 | 4.947 | 3.937 | 3.656 | 1.997 | 0.739 | 0.67 | 0.422 | 0.433 | 0.277 |
| Other Expenses
| 0 | 0 | -7.067 | 4.245 | 0 | 2.822 | 2.201 | 0 | 0 | 0 | 0.074 | 0 | 0 | 0 | 0 | 0 | -1.245 | -0.49 |
| Operating Expenses
| 22.213 | 20.881 | 18.598 | 18.33 | 21.805 | 22.329 | 21.111 | 19.835 | 19.626 | 15.131 | 15.106 | 12.062 | 6.734 | 2.664 | 1.655 | 1.256 | 1.106 | 0.826 |
| Operating Income
| -13.822 | -20.161 | -16.137 | -15.813 | -20.748 | -20.281 | -18.266 | -18.022 | -17.261 | -13.542 | -13.49 | -10.903 | -6.252 | -2.284 | -1.655 | -1.256 | -1.106 | -0.826 |
| Operating Income Ratio
| -1.554 | -16.103 | -6.557 | -6.282 | -19.629 | -9.903 | -6.42 | -9.94 | -7.299 | -8.522 | -8.348 | -9.407 | -12.971 | -6.011 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 7.863 | 5.401 | 4.379 | 4.245 | 3.24 | 2.822 | 2.201 | 1.326 | 0.373 | 0.132 | 0.074 | 0.137 | 0.046 | 0 | 0 | 0 | -1.245 | -0.49 |
| Income Before Tax
| -5.959 | -14.76 | -11.758 | -11.568 | -17.508 | -17.459 | -16.065 | -16.696 | -16.888 | -13.41 | -13.416 | -10.766 | -6.206 | -2.284 | -1.655 | -1.256 | -2.46 | -1.413 |
| Income Before Tax Ratio
| -0.67 | -11.789 | -4.778 | -4.596 | -16.564 | -8.525 | -5.647 | -9.209 | -7.141 | -8.439 | -8.302 | -9.289 | -12.876 | -6.011 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.489 | 0.953 | -0.5 | 0.349 | -0.453 | -4.805 | -2.652 | -0.373 | -0.264 | -0.074 | 0.137 | 0.046 | 0 | 0 | 0 | -1.136 | -0.393 |
| Net Income
| -5.959 | -14.76 | -11.758 | -11.568 | -17.508 | -17.459 | -11.26 | -14.044 | -16.515 | -13.146 | -13.416 | -10.766 | -6.206 | -2.284 | -1.655 | -1.256 | -2.46 | -1.413 |
| Net Income Ratio
| -0.67 | -11.789 | -4.778 | -4.596 | -16.564 | -8.525 | -3.958 | -7.746 | -6.983 | -8.273 | -8.302 | -9.289 | -12.876 | -6.011 | 0 | 0 | 0 | 0 |
| EPS
| -0.11 | -0.3 | -0.25 | -0.25 | -0.42 | -0.42 | -0.27 | -0.34 | -0.4 | -0.32 | -0.33 | -0.26 | -0.62 | -0.057 | -0.13 | -0.1 | -0.2 | -0.11 |
| EPS Diluted
| -0.11 | -0.3 | -0.25 | -0.25 | -0.42 | -0.42 | -0.27 | -0.34 | -0.4 | -0.32 | -0.33 | -0.26 | -0.62 | -0.057 | -0.13 | -0.1 | -0.2 | -0.11 |
| EBITDA
| -13.316 | -19.629 | -15.606 | -15.813 | -20.277 | -20.281 | -18.266 | -17.773 | -17.153 | -13.461 | -13.49 | -10.739 | -6.193 | -2.275 | -1.646 | -1.255 | -2.35 | -1.314 |
| EBITDA Ratio
| -1.497 | -15.678 | -6.341 | -6.282 | -19.184 | -9.903 | -6.42 | -9.803 | -7.253 | -8.471 | -8.348 | -9.266 | -12.849 | -5.987 | 0 | 0 | 0 | 0 |